MBQ Pharma announces the First-in-Human Dose of MBQ-167 for Advanced Breast Cancer in a Phase 1 Clinical Trial in Puerto Rico with the dual targeted Rac/Cdc42 inhibitor
Submitted on 4 December 2023 - 11:22am
This article is reproduced by CienciaPR with permission from the original source.